Alglucosidase alfa
Therapetic Alglucosidase alfa enzyme from the original Myozyme® commercial drug.
Reference Standard as Aliquots
Product Batch | Therapeutic Expiry Date
| Brand & Origin
| Amount per Aliquot | Select Quantity | Discount | Price per Aliquot
| |
|---|---|---|---|---|---|---|---|
2025.12 |
Myozyme® DE |
5 mg |
Unit: aliquot(s) |
557,00 €
/aliquot
|
Biosimilars as Aliquots
Access Batch Specific Analytical Information
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Product Information
Here you will find the product information for the reference product.
Myozyme® / Alglucosidase alfa Reference Product
| Drug name | Myozyme® |
| INN | Alglucosidase alfa |
| API type | Enzyme |
| Pharmacotherapeutic group | Other alimentary tract and metabolism products, enzymes |
| ATC code | A16AB07 |
| Target of antibody | Lysosomal glycogen |
| General function | |
| Short description | Alglucosidase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid α-glucosidase deficiency). Alglucosidase alfa is indicated in adults and paediatric patients of all ages. |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | It is postulated that Myozyme will restore lysosomal GAA activity resulting in stabilisation or restoration of cardiac and skeletal muscle function (including respiratory muscles). Due to the blood-brain barrier effect and the enzyme’s size, uptake of alglucosidase alfa in the central nervous system is unlikely. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Pompe disease is a rare, progressive and fatal metabolic myopathy with an estimated global incidence of 1 in 40,000 births. Other names for Pompe disease include glycogen storage disease type II (GSD-II), acid maltase deficiency (AMD) and glycogenosis type II. Pompe disease belongs to the lysosomal storage disorders as it is caused by a deficiency of a naturally occurring lysosomal hydrolase, acid α-glucosidase (GAA) that degrades lysosomal glycogen to glucose. Deficiency of this enzyme leads to glycogen accumulation in various tissues, particularly cardiac, respiratory and skeletal muscle, leading to the development of hypertrophic cardiomyopathy and progressive muscle weakness, including impairment of respiratory function. |
| Original license holder | Sanofi B.V. Paasheuvelweg 25 1105 BP Amsterdam The Netherlands |
| Marketing authorisation numbers | EU/1/06/333/001-003 |
| Marketing authorisation holder | Sanofi B.V. Paasheuvelweg 25 1105 BP Amsterdam The Netherlands |
| Name of the manufacturer of the biological active substance | Genzyme Corporation 45, 51, 76, 74 and 80 New York Avenue, Framingham, MA 01701, United States Genzyme Flanders, Cipalstraat 8, 2440 Geel, Belgium |
| Name and address of the manufacturer(s) responsible for batch release | Genzyme Ireland Limited, IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland |
| Max shelf life | 3 years |
| Storage conditions | 2°C – 8°C |
| List of excipients | Mannitol (E421) Sodium dihydrogen phosphate monohydrate (E339) Disodium phosphate heptahydrate (E339) Polysorbate 80 (E433) |
Support
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Ready to simplify your sourcing?
Here’s how to get started:
Select Your Licensed Molecules
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Get a Quote
Receive a confidential, non-binding quote for the molecule(s) you choose.
Get Qualified & We Deliver
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.
Do you have a question you'd like to ask us?
Here’s how to get started:
